Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Relapsing multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Current treatments aim to reduce disease activity and disability progression.
• Glatiramer acetate (GA) is a disease-modifying therapy for MS.

Purpose of the Study:

• To evaluate the efficacy of rituximab induction followed by glatiramer acetate (GA) monotherapy compared to GA monotherapy alone in patients with active relapsing MS.
• To assess the proportion of patients achieving no evidence of disease activity (NEDA).

Main Methods:

• A single-center, double-blind, placebo-controlled study involving 55 participants with relapsing MS.
• Participants were randomized to receive either rituximab (R-GA) or placebo (P-GA) induction, followed by GA therapy for all.
• Follow-up extended to 3 years, with NEDA defined as absence of relapse, new MRI lesions, and sustained disability change.

Main Results:

• The R-GA group showed a significantly higher rate of NEDA (44.44%) compared to the P-GA group (19.23%) (p=0.049).
• Treatment failure was less frequent and occurred later in the R-GA arm (37.04% vs 69.23%, p=0.019).
• Fewer new T2 lesions were observed in the R-GA group (0.48 vs 1.96, p=0.027), though NEDA benefit waned over time.

Conclusions:

• Rituximab induction followed by GA may offer short-term superior efficacy over GA alone for active relapsing MS.
• The observed benefit in achieving NEDA appears to diminish within the study duration.
• Larger studies are required to confirm the long-term sustainability of these findings.